Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.003
Sell
RSI(14)
44.931
Neutral
STOCH(KDJ)(9,3,3)
32.355
Buy
ATR(14)
0.082
Low Volatility
CCI(14)
-63.460
Neutral
Williams %R
67.559
Sell
TRIX(12,20)
-0.244
Sell
StochRSI(14)
100.000
Buy
Bionano Genomics Inc
BNGO1.600USD
+0.010+0.63%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
15.57MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Bionano Genomics Inc
Currency: USD Updated: 2025-12-19Key Insights
Bionano Genomics Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 148/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.50.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Bionano Genomics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
3
analysts
Buy
Current Rating
7.500
Target Price
+357.32%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Bionano Genomics Inc Highlights
StrengthsRisks
Bionano Genomics, Inc. is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).
Growing
The company is in a growing phase, with the latest annual income totaling USD 30.78M.
Overvalued
The company’s latest PE is -0.00, at a high 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-19The current financial score of Bionano Genomics Inc is 6.01, ranking 178/208 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 7.37M, representing a year-over-year increase of 21.31%, while its net profit experienced a year-over-year increase of 80.78%.
Score
Financials
5.55
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.13
Operational Efficiency
4.19
Growth Potential
6.11
Shareholder Returns
7.07
Bionano Genomics Inc's Company Valuation
Currency: USD Updated: 2025-12-19The current valuation score of Bionano Genomics Inc is 8.18, ranking 47/208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -0.00, which is 0.00% below the recent high of -0.00 and -1432166.67% above the recent low of -4.30.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 148/208
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-19The current earnings forecast score of Bionano Genomics Inc is 7.33, ranking 137/208 in the Healthcare Equipment & Supplies industry. The average price target for Bionano Genomics Inc is 7.50, with a high of 8.00 and a low of 7.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
7.500
Target Price
+357.32%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
90
Total
4
Median
7
Average
Company name
Ratings
Analysts
Bionano Genomics Inc
BNGO
3
Boston Scientific Corp
BSX
36
Edwards Lifesciences Corp
EW
34
Veeva Systems Inc
VEEV
34
Intuitive Surgical Inc
ISRG
34
Thermo Fisher Scientific Inc
TMO
27
1
2
3
...
18
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-19The current price momentum score of Bionano Genomics Inc is 1.23, ranking 206/208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 1.84 and the support level at 1.41, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.564
Buy
MA10
1.608
Sell
MA20
1.664
Sell
MA50
1.728
Sell
MA100
2.330
Sell
MA200
2.959
Sell
Institutional Confidence
Currency: USD Updated: 2025-12-19The current institutional shareholding score of Bionano Genomics Inc is 3.00, ranking 135/208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 2.31%, representing a quarter-over-quarter decrease of 10.20%. The largest institutional shareholder is The Vanguard, holding a total of 50.46K shares, representing 0.50% of shares outstanding, with 70.16% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2025-12-19The current risk assessment score of Bionano Genomics Inc is 1.63, ranking 185/208 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.14. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
1.14
VaR
+8.16%
240-Day Maximum Drawdown
+91.24%
240-Day Volatility
+110.48%
Return
Best Daily Return
60 days
+8.72%
120 days
+21.11%
5 years
+42.87%
Worst Daily Return
60 days
-8.45%
120 days
-35.74%
5 years
-35.74%
Sharpe Ratio
60 days
-0.37
120 days
-1.00
5 years
-1.37
Risk Assessment
Maximum Drawdown
240 days
+91.24%
3 years
+99.86%
5 years
+99.97%
Return-to-Drawdown Ratio
240 days
-0.99
3 years
-0.33
5 years
-0.20
Skewness
240 days
+0.09
3 years
+0.56
5 years
+0.73
Volatility
Realised Volatility
240 days
+110.48%
5 years
+101.16%
Standardised True Range
240 days
+21.51%
5 years
+4722.34%
Downside Risk-Adjusted Return
120 days
-104.07%
240 days
-104.07%
Maximum Daily Upside Volatility
60 days
+50.87%
Maximum Daily Downside Volatility
60 days
+38.12%
Liquidity
Average Turnover Rate
60 days
+3.67%
120 days
+34.32%
5 years
--
Turnover Deviation
20 days
-99.77%
60 days
-99.83%
120 days
-98.44%
Peer Comparison
Healthcare Equipment & Supplies
Bionano Genomics Inc
BNGO
4.90 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
EW
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LivaNova PLC
LIVN
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
AORT
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
LNTH
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Tactile Systems Technology Inc
TCMD
8.43 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Bionano Genomics Inc?
The TradingKey Stock Score provides a comprehensive assessment of Bionano Genomics Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Bionano Genomics Inc’s performance and outlook.
How do we generate the financial health score of Bionano Genomics Inc?
To generate the financial health score of Bionano Genomics Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Bionano Genomics Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Bionano Genomics Inc.
How do we generate the company valuation score of Bionano Genomics Inc?
To generate the company valuation score of Bionano Genomics Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Bionano Genomics Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Bionano Genomics Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Bionano Genomics Inc.
How do we generate the earnings forecast score of Bionano Genomics Inc?
To calculate the earnings forecast score of Bionano Genomics Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Bionano Genomics Inc’s future.
How do we generate the price momentum score of Bionano Genomics Inc?
When generating the price momentum score for Bionano Genomics Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Bionano Genomics Inc’s prices. A higher score indicates a more stable short-term price trend for Bionano Genomics Inc.
How do we generate the institutional confidence score of Bionano Genomics Inc?
To generate the institutional confidence score of Bionano Genomics Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Bionano Genomics Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Bionano Genomics Inc.
How do we generate the risk management score of Bionano Genomics Inc?
To assess the risk management score of Bionano Genomics Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Bionano Genomics Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Bionano Genomics Inc.
